This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
BEAM Focuses on Developing Gene Drug for Growth
by Zacks Equity Research
While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.
PFENegative Net Change VRTXNegative Net Change BEAMNegative Net Change CRSPNegative Net Change
biotechnology crispr gene-editing medical
Should You Buy ESS Tech, Inc. (GWH) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
GWHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Jasper (JSPR) Up on FDA Nod to Begin Early-Stage Urticaria Study
by Zacks Equity Research
Jasper (JSPR) announces the FDA clearance to begin the clinical study of briquilimab for chronic spontaneous urticaria. The stock of the company rises 16%.
NVSNegative Net Change CORTNegative Net Change JSPRPositive Net Change BTTXNo Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B
by Zacks Equity Research
Bristol Myers (BMY) to offset its declining revenues from top drugs with the acquisition of Mirati Therapeutics, which will add lung cancer drug Krazati to its portfolio.
NVSNegative Net Change BIIBNegative Net Change BMYNegative Net Change MRTXPositive Net Change
biotechnology biotechs pharmaceuticals
Progressive (PGR)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PGRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Arcutis (ARQT) Up on FDA Nod for Zoryve Label Expansion
by Zacks Equity Research
Arcutis (ARQT) gains on receiving FDA approval for label expansion of Zoryve (roflumilast) cream 0.3% to treat patients in the age group of 6-11 years with plaque psoriasis.
CORTNegative Net Change ANIKNegative Net Change ANVSNegative Net Change ARQTNegative Net Change
biotechnology medical
Bear of the Day: Illumina (ILMN)
by Kevin Cook
Contracting margins, antitrust over GRAIL, and the Icahn invasion all crash estimates and shares
ILMNNegative Net Change
biotechnology cancer genetic-testing genomics oncology-screening smart-health
Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery
by Zacks Equity Research
Bayer (BAYRY) collaborates with Twist Bioscience to advance breakthrough innovations based on new scientific approaches and platform technologies.
REGNNegative Net Change BAYRYNegative Net Change TWSTNegative Net Change ETONNegative Net Change
biotechnology biotechs pharmaceuticals
uniQure (QURE) Up on Restructuring Plans, Workforce Reduction
by Zacks Equity Research
uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.
DVAXNegative Net Change QURENegative Net Change ETONNegative Net Change
biotechnology biotechs pharmaceuticals
Apellis (APLS) Provides Syfovre Q3 Preliminary Revenues Guidance
by Zacks Equity Research
Apellis' (APLS) shares rise as it provides third-quarter 2023 preliminary revenues guidance for Syfovre, approved for the treatment of geographic atrophy.
CORTNegative Net Change ANIKNegative Net Change APLSNegative Net Change ANVSNegative Net Change
biotechnology medical
Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study
by Zacks Equity Research
Lineage (LCTX) rises 10% on positive imaging analyses results from the phase I/IIa study of OpRegen in patients with geographic atrophy secondary to age-related macular degeneration.
RHHBYNegative Net Change CORTNegative Net Change LCTXNegative Net Change BTTXNo Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why
by Zacks Equity Research
Structure Therapeutics (GPCR) rises 9% on encouraging initial data from the early-stage study of its pipeline candidate, GSBR-1290, in healthy overweight or obese individuals.
NVONegative Net Change LLYNegative Net Change ANIKNegative Net Change GPCRNegative Net Change
biotechnology medical
Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin
by Zacks Equity Research
Orchard (ORTX) is set to be acquired by Kyowa Kirin for a consideration of $17 per American Depositary Share, which amounts to a total transaction value of approximately $478 million. Shares rise 97%.
CORTNegative Net Change ORTXPositive Net Change ANVSNegative Net Change BTTXNo Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More
by Zacks Equity Research
Regulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector.
REGNNegative Net Change MRNANegative Net Change NVAXNegative Net Change NTLAPositive Net Change ALXONegative Net Change
biotechnology pharmaceuticals
Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data
by Zacks Equity Research
Nuvalent (NUVL) surges 36% on encouraging preliminary results from the phase I dose-escalation portion of its early-mid-stage development program for NVL-655 to treat advanced ALK-positive NSCLC.
PFENegative Net Change CORTNegative Net Change NUVLNegative Net Change BTTXNo Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi (SNY) Signs Deal to Co-Develop Teva's IBD Candidate
by Zacks Equity Research
Sanofi (SNY) and Teva enter into a collaboration deal to co-develop and co-commercialize the latter's inflammatory bowel disease candidate, TEV'574.
SNYNegative Net Change TEVANegative Net Change CORTNegative Net Change BTTXNo Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce
by Zacks Equity Research
Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.
CORTNegative Net Change KZRNegative Net Change ANVSNegative Net Change BTTXNo Net Change
biotechnology biotechs medical pharmaceuticals
Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies
by Zacks Equity Research
Intellia (NTLA) expands partnership with Regeneron, to develop potential treatments for neurological and muscular diseases.
REGNNegative Net Change ANIKNegative Net Change NTLAPositive Net Change ANVSNegative Net Change
biotechnology crispr gene-editing gene-therapy medical
Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why
by Zacks Equity Research
Kinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization efforts and slash workforce by 70%.
PFENegative Net Change CORTNegative Net Change BTTXNo Net Change
biotechnology biotechs gene-editing genomics medical pharmaceuticals
Apellis' (APLS) Empaveli Injector Gets FDA Nod for PNH
by Zacks Equity Research
Apellis (APLS) receives the FDA approval for Empaveli Injector, a self-administred on-body device, to treat patients with paroxysmal nocturnal hemoglobinuria.
CORTNegative Net Change ANIKNegative Net Change APLSNegative Net Change ANVSNegative Net Change
biotechnology medical
NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up
by Zacks Equity Research
NRx Pharma (NRXP) receives FDA clearance to begin clinical development for its lead candidate, NRX-101, to treat chronic pain.
CORTNegative Net Change ANIKNegative Net Change ANVSNegative Net Change NRXPPositive Net Change
biotechnology medical
Madrigal (MDGL) to Raise Capital Via Public Offering of $500M
by Zacks Equity Research
Madrigal (MDGL) is raising funds through a public offering of 1.25 million shares of its common stock to use in commercial activities in the preparation of a potential launch of resmetirom in the United States.
ICPTPositive Net Change VKTXNegative Net Change MDGLNegative Net Change
biotechnology pharmaceuticals
Baudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug Tag
by Zacks Equity Research
FDA grants the Orphan Drug designation to Baudax (BXRX) for its lead pipeline candidate, TI-168, to treat Hemophilia A patients with inhibitors.
SNYNegative Net Change RHHBYNegative Net Change PFENegative Net Change
biotechnology medical
PTC Therapeutics (PTCT) to Cut 25% Jobs by January 2024
by Zacks Equity Research
PTC Therapeutics (PTCT) will reduce its workforce in accordance with its strategic prioritization process. It will also submit a re-examination request for the negative CHMP opinion on Translarna.
RHHBYNegative Net Change DVAXNegative Net Change PTCTNegative Net Change ETONNegative Net Change
biotechnology pharmaceuticals
Should You Buy Western Union (WU) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
WUNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines